Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) CFO William J. Peters Sells 7,426 Shares

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) CFO William J. Peters sold 7,426 shares of the stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $52.05, for a total transaction of $386,523.30. Following the transaction, the chief financial officer now owns 94,103 shares in the company, valued at approximately $4,898,061.15. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Amphastar Pharmaceuticals Trading Up 4.8 %

NASDAQ AMPH opened at $48.31 on Monday. The firm has a market cap of $2.35 billion, a PE ratio of 16.10, a price-to-earnings-growth ratio of 1.02 and a beta of 0.82. Amphastar Pharmaceuticals, Inc. has a 52 week low of $36.56 and a 52 week high of $65.92. The company has a quick ratio of 2.63, a current ratio of 3.52 and a debt-to-equity ratio of 0.82. The company has a 50 day moving average price of $48.44 and a 200 day moving average price of $44.23.

Institutional Trading of Amphastar Pharmaceuticals

Institutional investors have recently made changes to their positions in the business. Silvercrest Asset Management Group LLC raised its stake in Amphastar Pharmaceuticals by 35.1% in the first quarter. Silvercrest Asset Management Group LLC now owns 112,428 shares of the company’s stock valued at $4,937,000 after buying an additional 29,182 shares during the last quarter. International Assets Investment Management LLC acquired a new position in shares of Amphastar Pharmaceuticals during the third quarter valued at about $11,070,000. Intech Investment Management LLC purchased a new position in shares of Amphastar Pharmaceuticals in the 2nd quarter valued at approximately $426,000. Granite Investment Partners LLC boosted its stake in Amphastar Pharmaceuticals by 12.7% in the 2nd quarter. Granite Investment Partners LLC now owns 397,514 shares of the company’s stock worth $15,901,000 after purchasing an additional 44,744 shares in the last quarter. Finally, 1620 Investment Advisors Inc. purchased a new stake in Amphastar Pharmaceuticals during the 2nd quarter worth approximately $93,000. Institutional investors and hedge funds own 65.09% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, August 8th. Piper Sandler dropped their target price on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating on the stock in a research report on Thursday, August 8th. Finally, StockNews.com lowered Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, Amphastar Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $63.00.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.